Share on StockTwits

OraSure Technologies (NASDAQ:OSUR) shares saw strong trading volume on Wednesday after Mizuho raised their price target on the stock from $9.00 to $10.00, Analyst Ratings.Net reports. Mizuho currently has a buy rating on the stock. 2,678,391 shares were traded during mid-day trading, an increase of 394% from the previous session’s volume of 542,678 shares.The stock last traded at $7.50 and had previously closed at $7.23.

Several other analysts have also recently commented on the stock. Analysts at TheStreet downgraded shares of OraSure Technologies from a “hold” rating to a “sell” rating in a research note on Wednesday. Separately, analysts at Raymond James reiterated an “outperform” rating on shares of OraSure Technologies in a research note on Thursday, May 8th. They now have a $8.50 price target on the stock, down previously from $10.00. Finally, analysts at Cowen and Company raised their price target on shares of OraSure Technologies from $8.00 to $9.00 in a research note on Friday, May 2nd. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $8.42.

The stock’s 50-day moving average is $6.45 and its 200-day moving average is $6.66. The company’s market cap is $417.7 million.

OraSure Technologies (NASDAQ:OSUR) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($0.10) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.13) by $0.03. The company had revenue of $23.50 million for the quarter, compared to the consensus estimate of $23.28 million. During the same quarter in the prior year, the company posted ($0.18) earnings per share. The company’s quarterly revenue was up 10.8% on a year-over-year basis. Analysts expect that OraSure Technologies will post $-0.25 EPS for the current fiscal year.

OraSure Technologies, Inc, is engaged in development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using the Company’s oral fluid technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.